Non-HDL @entity165 is a better target for predicting periprocedural @entity296 following percutaneous coronary intervention in XXXX .

@entity1 @entity2175 @entity296 @entity6 @entity2299 @entity453 @entity165
OBJECTIVE: Non-HDL @entity165 (non-HDL-C) has recently been recommended as a first target for @entity2299 management. We previously reported that LDL @entity165 (LDL-C) and non-HDL-C levels were similarly associated with periprocedural @entity296 (PMI) following percutaneous coronary intervention (PCI) in @entity1 with @entity453 . Here we investigated the comparative prognostic value of non-HDL-C and LDL-C for PMI following PCI in @entity2175 ( @entity2175 ). METHODS: We prospectively enrolled 1194 consecutive @entity2175 @entity1 with normal preprocedural cTnI undergoing PCI. @entity1 were divided into the two groups: group A [glycated hemoglobin (HbA1c)  <  7%, n  =  567] and group B (HbA1c  >=   7%, n  =  627). PMI was evaluated by cTnI analysis within 24  h. The relationship of preprocedural non-HDL-C and LDL-C levels with peak cTnI values after PCI was examined. RESULTS: @entity1 in group B, with higher preprocedural non-HDL-C levels, had higher postprocedural cTnI levels (b  =  0.102, P  =  0.011). In the multivariable model, a 1-SD increase in non-HDL-C produced a 30% and 33% increased risk of postprocedural cTnI >3  *  upper limit of normal (ULN) and >5  *  ULN in group B, respectively. However, neither LDL-C nor group A @entity1 were affected. Furthermore, @entity1 with non-HDL-C levels >= 130  mg/dl compared with non-HDL-C levels  <=100  mg/dl were associated with a 83.3% and 71.7% increased risk of postprocedural cTnI >3  *  ULN and >5  *  ULN in group B, respectively. CONCLUSIONS: In poorly-controlled @entity6 @entity1 (HbA1c  >=   7%) undergoing PCI, non-HDL-C but not LDL-C was independently associated with and increased risk of PMI, and non-HDL-C levels >= 130  mg/dl had a worse PMI risk profile compared with non-HDL-C levels <100  mg/dl.
